[Molecular diagnostic testing in gliomas].
Glial tumours represent the majority of central nervous system tumours. Even though current therapy guidelines do not advocate the routine use of molecular markers for treatment decisions, the identification of prognostic markers and patient subgroups that may especially benefit from novel therapeutic options becomes increasingly important also outside the setting of clinical trials. This review summarizes methods and rationale for the use of the determination of 1p/19q loss, MGMT promoter methylation and tyrosine kinase receptor expression as diagnostic, prognostic and predictive markers in gliomas.
Hasselblatt
M
M
Institut für Neuropathologie, Universitätsklinikum Münster, Domagkstrasse 19, 48129, Münster, Deutschland. hasselblatt@uni-muenster.de
D014408:Biomarkers, Tumor / Q000235:genetics; D001932:Brain Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D005910:Glioma / Q000145:classification / Q000235:genetics* / Q000473:pathology; D006801:Humans; D025202:Molecular Diagnostic Techniques; D011237:Predictive Value of Tests; D011379:Prognosis
D014408:Biomarkers, Tumor
J Clin Oncol. 1998 Oct;16(10):3310-5
9779706
Cancer Res. 1999 Feb 15;59(4):793-7
10029064
J Clin Oncol. 2007 Oct 20;25(30):4722-9
17947719
Science. 2007 Oct 12;318(5848):287-90
17872411
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
J Neurooncol. 2007 May;83(1):17-29
17206475
Neuro Oncol. 2006 Jan;8(1):27-37
16443945
Pediatr Blood Cancer. 2007 Apr;48(4):403-7
16609952
J Neurooncol. 2004 Mar-Apr;67(1-2):159-65
15072463
Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):59-65
18091318
J Clin Oncol. 2008 Jan 10;26(2):271-8
18182667
J Clin Oncol. 2006 Jun 20;24(18):2715-22
16782911
N Engl J Med. 2005 Nov 10;353(19):2012-24
16282176
Anal Biochem. 2008 Jun 1;377(1):62-71
18384736
Int J Cancer. 2007 Dec 1;121(11):2458-64
17691113
J Mol Diagn. 2006 Sep;8(4):433-43
16931583
N Engl J Med. 2000 Nov 9;343(19):1350-4
11070098
J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15
18091559
Acta Neuropathol. 2008 Feb;115(2):249-59
17965865
Science. 2006 May 26;312(5777):1175-8
16728632
Clin Cancer Res. 2004 Mar 15;10(6):1871-4
15041700
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
Nat Rev Cancer. 2004 Apr;4(4):296-307
15057289
J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51
17549014
J Mol Diagn. 2007 Jul;9(3):368-81
17591937
Am J Pathol. 1994 Nov;145(5):1175-90
7977648
Cancer. 1997 Apr 1;79(7):1381-93
9083161
Int J Cancer. 2005 Jan 20;113(3):379-85
15455350
J Clin Oncol. 2000 Feb;18(3):636-45
10653879
Lab Invest. 2007 Apr;87(4):392-7
17260000
Brain Pathol. 2008 Oct;18(4):520-32
18400046
J Clin Oncol. 2005 Dec 20;23(36):9359-68
16361636